Erudio Healtherudio.com
Indication
AL amyloidosis
1 HCP commentary report on clinical trials in AL amyloidosis. Each report covers what clinicians said in public about one trial, with the source behind every view.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| LINKER-AL2 NCT06292780 · Regeneron Pharmaceuticals | relapsed or refractory systemic light chain amyloidosis | Phase 1/Phase 2 | 149 | 25 | Focused 64 from 10 confirmed clinicians | Nov 1, 2026 | Preview |